Search Results | NIH

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Search Results 2601 – 2620 of 3231

What's New in the Guidelines

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/whats-new

Coccidioidomycosis

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/coccidioidomycosis

What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient

https://clinicalinfo.hiv.gov/guidelines/adult-and-adolescent-arv/what-start-initial-combination-regimens-antiretroviral-naive-1

Table 1. Chemoprophylaxis to Prevent First Episode of Opportunistic Disease

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/prophylaxis-prevent-first-episode

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/tenofovir-df

Progressive Multifocal Leukoencephalopathy/JC Virus Infection

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/progressive

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/overview-1

Pregnancy and Postpartum HIV Testing and Identification of Perinatal and Postnatal HIV Exposure

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/maternal-hiv-testing-and-identification-perinatal-hiv-exposure

Treatment Goals

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/treatment-goals

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/syphilis

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/giardiasis

Clinical and Laboratory Monitoring of Pediatric HIV Infection

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/clinical-and-laboratory-monitoring-pediatric-hiv-infection

Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/appendix-a-table-2-antiretroviral-fixed-dose-combination-tablets-and-copackaged-formulations

Herpes Simplex Virus

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/herpes-simplex-virus

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/leishmaniasis

Mycobacterium tuberculosis

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/mycobacterium-tuberculosis

Lamivudine (Epivir, 3TC)

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-nrtis-lamivudine-epivir

Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/appendix-table-1-antiretrovirals-available-fixed

Human Herpesvirus-8 Disease

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/human-herpesvirus

Table 6. Dosing Recommendations for Drugs Used to Treat or Prevent Opportunistic Infections that Require Dosage Adjustment in Adults With Renal Insufficiency

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/dosing-recommendations-drugs-used